N/A
N=31
Efficacy of Twice Weekly Hemodialysis in Patients With Residual Kidney Function
Hemodialysis · Kidney Failure, Chronic
Bottom Line
View on ClinicalTrials.gov: NCT03874117 ↗Enrolled (actual)
31
Serious AEs
0.0%
Results posted
Sep 2025
Primary outcome: Primary: QOL: Kidney Disease Quality of Life (KDQOL36) — 74; 72 score on a scale
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Twice Weekly Hemodialysis then Thrice Weekly Hemodialysis (Other); Thrice Weekly Hemodialysis then Twice Weekly Hemodialysis (Other)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Palo Alto Veterans Institute for Research
- Primary completion
- Sep 2024
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY QOL: Kidney Disease Quality of Life (KDQOL36) |
74; 72 | — |
| SECONDARY Solute Concentration |
3.6; 3.6 | — |
| SECONDARY Symptom |
26; 32 | — |
| SECONDARY Trail B Making Test |
129; 125 | — |
| SECONDARY Digit Symbol Substitution Test |
51; 51 | — |
Summary
The study will determine the efficacy of twice weekly hemodialysis in patients with residual kidney function.
Eligibility Criteria
Inclusion Criteria
- patients on hemodialysis who have residual kidney function with residual urea clearance (Kru) >2.5 mL/min.
- been on hemodialysis for at least 3 months.
- adherence to regular dialysis treatments.
Exclusion Criteria
- inability to achieve adequate hemodialysis.
- planned revision of hemodialysis vascular access.
- hospitalized within the past 2 months.
Data sourced from ClinicalTrials.gov (NCT03874117). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.